Love Hemp Group Plc operates as a dynamic investment firm, providing both venture capital and private equity to businesses at various growth stages, from nascent startups to established enterprises, and pursuing strategic acquisitions. Its investment strategies are flexible, encompassing debt or equity financing, whether in publicly traded or private securities. The firm can take direct stakes in companies, partnerships, joint ventures, or specific projects, and also utilize licensing agreements. The company primarily focuses its capital on the rapidly expanding Cannabidiol (CBD) and broader cannabis/hemp sectors. This includes companies engaged in CBD wellness, medicinal cannabis, and industrial hemp, particularly those developing therapeutic cannabis derivatives such as nutraceuticals, dietary supplements, and cosmetic formulations. Its investment scope spans the entire value chain of these industries, covering the cultivation of cannabis and hemp, the development and production of premium CBD products (such as oils, edibles, cosmetics, and capsules), manufacturing and distributing medicinal cannabis/hemp/CBD items, and the commercialization of cannabis pharmacology. It also backs ventures involved in professional prescription, patient aftercare, data management, laboratory testing, and regulatory compliance for these sectors. Within the CBD wellness market, it supports the creation of diverse retail offerings, including patches, topical ointments, tinctures, beverages, powdered supplements, vaping capsules, e-liquids, and oils. Geographically, Love Hemp Group Plc targets opportunities across a broad international spectrum, including Europe (with a specific presence in the UK, Germany, and Netherlands), North America (Canada), Australia, Japan, Thailand, Africa, South America, Israel, and the wider Asian market. While typically adopting a medium to long-term investment horizon, the firm remains agile, pursuing shorter-term opportunities when strategically advantageous. Primarily, Love Hemp Group Plc aims to secure majority stakes, thereby gaining controlling influence; however, it also considers non-controlling, minority investments when appropriate. Established on January 30, 2019, the company is headquartered in London, United Kingdom, with additional local offices.